search
Back to results

Effect of PRM-125 on Ambulatory Blood Pressure

Primary Purpose

Hypertension

Status
Withdrawn
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
PRM-125
Sponsored by
PRM Pharma, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

30 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • primary hypertension

Exclusion Criteria:

  • medical conditions that preclude evaluation and/or adversely effect subject safety

Sites / Locations

  • AMR

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

PRM125

Arm Description

PRM125

Outcomes

Primary Outcome Measures

Change in 24 hour Systolic Blood Pressure

Secondary Outcome Measures

Change in 24 hour Diastolic Blood Pressure

Full Information

First Posted
January 2, 2022
Last Updated
March 16, 2023
Sponsor
PRM Pharma, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05195827
Brief Title
Effect of PRM-125 on Ambulatory Blood Pressure
Official Title
Evaluation of Once-Daily PRM125 On Ambulatory Blood Pressure in Adults With Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Withdrawn
Why Stopped
Sponsor
Study Start Date
December 20, 2021 (Actual)
Primary Completion Date
September 30, 2022 (Actual)
Study Completion Date
November 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
PRM Pharma, LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Evaluation of Once-Daily PRM125 On Ambulatory Blood Pressure in Adults with Hypertension
Detailed Description
Approximately 60 subjects with primary hypertension are treated for 8 weeks with PRM125 to determine if Ambulatory Blood Pressure is changed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
PRM125
Arm Type
Experimental
Arm Description
PRM125
Intervention Type
Drug
Intervention Name(s)
PRM-125
Intervention Description
Antihypertensive
Primary Outcome Measure Information:
Title
Change in 24 hour Systolic Blood Pressure
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Change in 24 hour Diastolic Blood Pressure
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: primary hypertension Exclusion Criteria: medical conditions that preclude evaluation and/or adversely effect subject safety
Facility Information:
Facility Name
AMR
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33134
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of PRM-125 on Ambulatory Blood Pressure

We'll reach out to this number within 24 hrs